Onesource Specialty Pharma Limited · NSE:ONESOURCE
Onesource Specialty Pharma — Q2 FY2027 Earnings Presentation
15 slides from Onesource Specialty Pharma's earnings presentation, Oct 27, 2026
Slide 1: Investor Presentation | Q2FY27
Investor Presentation | Q2FY27 October 27th, 2026 0
Slide 2: Safe Harbor Statement
Safe Harbor Statement Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "i
Slide 3: New DDC capacity drives strong YoY revenue and EBITDA growth
New DDC capacity drives strong YoY revenue and EBITDA growth ( Q2FY27 Performance Snapshot ) ₹5,162m Revenue “Q2 delivered strong sequential growth, led by new DDC $54.2m 37% YoY 15% QoQ capacity. With our second cartridge line commercial, H2 will see new launches and a significant ramp-up in commer
Slide 4: Q2FY27: Revenue up 37% YoY and EBITDA up 53% YoY
Q2FY27: Revenue up 37% YoY and EBITDA up 53% YoY In ₹m Q2FY27 YoY QoQ Q1FY27 Financial Snapshot Revenue 5,162 +37% +15% 4,490 EBITDA 1,633 +53% +32% 1,233 • Revenue of ₹5,162m/ $54.2m ↑37% YoY and ↑15% QoQ, our third EBITDA margin (%) 31.6% +329bps +416bps 27.5% consecutive quarter of sequential Rep
Slide 5: Business & Operational Updates
Business & Operational Updates Q2FY27
Slide 6: New capacity coming online as launches and partnerships build across businesses
New capacity coming online as launches and partnerships build across businesses Q2FY27 at a Glance 6 2 2x 12 75+ New wins New logos Sterile production days1 New launches Active RFPs including 2 in Biologics bringing total logo count to 82+ line 2 commercialised North America, MENA, LatAm biologics,
Slide 7: DDC capacity to triple for FY28: Two cartridge lines commercial, line 3 FAT completed
DDC capacity to triple for FY28: Two cartridge lines commercial, line 3 FAT completed Maintaining cold-chain integrity throughout the sterile manufacturing process Cartridge filling Visual inspection Pen assembly Labelling Packaging Warehousing Aseptic fill of drug Automated and manual Cartridge int
Slide 8: Biologics platform gaining momentum, with new customer wins and robust funnel
Biologics platform gaining momentum, with new customer wins and robust funnel Integrated DS-DP-Device Development Drug substance Drug product Device Gene to IND, IND to BLA Mammalian and Microbial Vials, PFS, high-viscosity Pens and autoinjectors One contract, one audit, no cold-chain handoff betwee
Slide 9: Business Outlook
Business Outlook ONe€SOUICE
Slide 10: Reaffirming FY28 outlook of $400M organic revenue and $160M EBITDA
Reaffirming FY28 outlook of $ 400M organic revenue and $ 160M EBITDA $ 400M 40% Revenue (organic) Steady state EBITDA margin STRATEGIC PILLARS FOR OUR GROWTH DDCs (including GLP-1s) BIOLOGICS BASE BUSINESS Scaling across markets and customers, Biologics funnel expanding with Sterile injectable and s
Slide 11: Q2FY27 Earnings Call Details
Q2FY27 Oct Day: Tuesday 27 Schedule: Date: 27th October 2026 Time: 06:30 PM IST Neeraj Sharma, CEO & MD Speakers: Anurag Bhagania, CFO +91 22 6280 1372 Dial In: +91 22 7115 8193 Diamond Pass: Click here for early registration
Slide 12: OneSource at a glance
OneSource at a glance
Slide 13: Building a pure-play CDMO platform with extensive capabilities and robust financial metrics
Building a pure-play CDMO platform, distinguished by extensive capabilities and robust financial metrics ROBUST MANUFACTURING & PRESENCE ACROSS HIGHLY ATTRACTIVE EXPERT PROFESSIONALS AND ONE-OF-ITS-KIND COMPLIANCE TRACK RECORD MODALITIES INCLUDING GLP-1 FINANCIAL PROFILE SEASONED BOARD #1 5 Multiple
Slide 14: ESG progress validated with ratings and recognition
ESG progress validated with ratings and recognition Latest Rating Updates Rewards & Recognition NSE Sustainability Ratings & Analytics 73/100 Received the Sustainability Excellence Award at the 5th National Sustainability Excellence Award “Leader” category among NSE-listed peers Bharat CSR & Sustain
Slide 15: Get in touch with us
Get in touch with us REGISTERED AND CORPORATE OFFICE INVESTOR RELATIONS OneSource Specialty Pharma Ltd Investor-relations@onesourcecdmo.com Investor-relations@onesourcecdmo.com Registered Office: Unit No. 902, Cyber One, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai, Sanpada, Thane, Maharashtra, I
OneSource Specialty Pharma — Q2 FY2027 Earnings Presentation on 6ix